Changeflow GovPing Pharma & Drug Safety Phenoxy and Benzyloxy Substituted Psychoplastog...
Routine Rule Added Final

Phenoxy and Benzyloxy Substituted Psychoplastogens and Uses Thereof

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4448531A1 for Delix Therapeutics covering phenoxy and benzyloxy substituted psychoplastogens and their therapeutic uses. The patent application lists designations across 31 European states and territories. The compounds are classified under IPC C07D 487/04 with therapeutic applications including neurological and psychiatric conditions such as anxiety, Alzheimer's disease, and addiction disorders.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The European Patent Office published patent application EP4448531A1 for Delix Therapeutics covering phenoxy and benzyloxy substituted psychoplastogens and their therapeutic uses. The patent application claims compositions and methods of using these compounds for treating neurological and psychiatric conditions.

Pharmaceutical companies and researchers in the CNS drug development space should monitor the progression of this application through EPO examination. While the publication does not create immediate compliance obligations for third parties, potential competitors developing similar psychoplastogen compounds should review the pending claims for freedom-to-operate considerations.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

PHENOXY AND BENZYLOXY SUBSTITUTED PSYCHOPLASTOGENS AND USES THEREOF

Publication EP4448531A1 Kind: A1 Apr 08, 2026

Applicants

Delix Therapeutics, Inc.

Inventors

POWELL, Noel Aaron, CHYTIL, Milan, WAGNER, Florence F.

IPC Classifications

C07D 487/04 20060101AFI20251118BHEP A61P 25/00 20060101ALI20251118BHEP A61P 25/22 20060101ALI20251118BHEP A61P 25/28 20060101ALI20251118BHEP A61P 25/30 20060101ALI20251118BHEP A61K 9/00 20060101ALI20251118BHEP A61K 9/20 20060101ALI20251118BHEP A61K 9/48 20060101ALI20251118BHEP A61K 31/55 20060101ALI20251118BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4448531A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Intellectual property registration Pharmaceutical compounds
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!